Genentech in-licenses Amgen's AMG 282

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) received exclusive global rights from Amgen Inc. (NASDAQ:AMGN) to AMG 282, an antibody against IL-1 receptor-like 1 ( IL1RL1; ST2). The antibody prevents IL-33 from binding to the receptor. Genentech plans to run Phase II trials of the antibody to treat asthma and chronic obstructive pulmonary disease (COPD), but did not provide a timeline. ...